Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 43

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 43
---
 we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

The forward-looking statements in this Annual Report include, among other things, statements about:

•our anticipated savings related to our corporate restructuring and the associated headcount reduction, as well as the potential impacts on employee morale and productivity;

•our ability to identify partnering opportunities for our product candidates;

•the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and related preparatory work and the period during which the results of the trials will become available, as well as our research and development programs;

•our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

•our ability to obtain regulatory approval of RP-3467, RP-1664, and any of our other future product candidates that we develop;

•the expected impact of the strategic reprioritization of our research and development activities, including with respect to anticipated cost savings;

•our ability to identify and develop additional product candidates;

•business disruptions affecting the initiation, patient enrollment, development and operation of our clinical trials, including a public health emergency or pandemic;

•the evolving impact of macroeconomic events on our operations, supply chains, general economic conditions, our ability to raise additional capital, and the continuity of our business, including our preclinical studies and clinical trials. These events include health pandemics, changes in inflation and foreign exchange rates, the U.S. Federal Reserve raising interest rates, disruptions in access to bank deposits or lending commitments due to bank failures, and the Russia-Ukraine and Middle-East conflicts;

•our ability to enroll patients in clinical trials, to timely and successfully complete those trials and to receive necessary regulatory approvals;

•the timing of completion of enrollment and availability of data from our current preclinical studies and clinical trials, including ongoing clinical trials of RP-3467, RP-1664 and lunresertib;

•the expected timing of filings with regulatory authorities for any product candidates that we develop;

•our expectations regarding the potential market size and the rate and degree of market acceptance for any current or future product candidates that we develop;

•our ability to receive any milestone or royalty payments under our collaboration and license agreements;

•the effects of competition with respect to RP-3467, RP-1664, lunresertib, or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry;